Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Optimizing adipose-derived stem cell therapy for diabetic foot ulcers.

Cao J., Liu ZC., An WQ., Zhang S., Zhang X., Li LJ.

Animal Study on Diabetic Foot, Chronic Wound, Chronic Inflammation, Immune Modulation, published in World J Diabetes (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
World J Diabetes (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41278441
PMCID
PMC12635780
DOI
10.4239/wjd.v16.i11.109859

Abstract (original English)

Background Diabetic foot ulcers (DFUs) are a severe complication of diabetes and a leading cause of lower limb amputation due to impaired wound healing. Adipose-derived mesenchymal stem cells (ADSCs) have emerged as a promising therapeutic option for DFUs because of their angiogenic, immunomodulatory, and regenerative properties. However, studies on the molecular mechanisms and regulatory pathways of ADSCs in DFUs are limited. Aim To investigate the dose-response relationship, the optimal administration route, persistence, and molecular mechanisms of ADSCs in DFU healing. Methods In this study, human ADSCs were isolated and cultured, and their differentiation potential was characterized. A DFU mouse model was established to evaluate the dose-dependent effects and persistence of ADSCs administered subcutaneously or intramuscularly. Wound closure rate, angiogenesis, inflammation, and collagen deposition were assessed in the ADSC-treated and model groups. Additionally, in vitro experiments using human dermal fibroblasts and endothelial cells were conducted to elucidate the molecular mechanisms underlying ADSC-mediated wound healing. Results ADSC treatment significantly enhanced wound closure, promoted angiogenesis, modulated inflammatory responses, and accelerated tissue regeneration in the DFU model. Notably, the therapeutic efficacy and retention of ADSCs were influenced by both

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research